WO2005020998A1 - Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation - Google Patents

Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation Download PDF

Info

Publication number
WO2005020998A1
WO2005020998A1 PCT/IB2004/002875 IB2004002875W WO2005020998A1 WO 2005020998 A1 WO2005020998 A1 WO 2005020998A1 IB 2004002875 W IB2004002875 W IB 2004002875W WO 2005020998 A1 WO2005020998 A1 WO 2005020998A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
water insoluble
substantially water
insoluble excipient
tablet
Prior art date
Application number
PCT/IB2004/002875
Other languages
English (en)
Inventor
Romi Barat Singh
Pananchukunnath Manoj Kumar
Vishnubhotla Nagaprasad
Sanjeev Kumar Sethi
Rajiv Malik
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to EP04769278A priority Critical patent/EP1663226A1/fr
Publication of WO2005020998A1 publication Critical patent/WO2005020998A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • moxifloxacin is l-cyclopropyl-7- ([S, S]-2,8-diazabicyclo [4.3. 0] non-8-yl)-6-fluoro-l, 4-dihydro-8-methoxy-4-oxo-3-quinolonecarboxylic acid. It is an antiinfective agent and is known from U.S. Patent No. 4,990,517.
  • Moxifloxacin can be used for the treatment of various infections, like acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and community acquired pneumonia.
  • U.S. Patent No. 4,990,517 discloses a pharmaceutical preparation that includes the active compound, with microcrystalline cellulose, maize starch, poly- (l-vinyl)-2- pyrrolidone (insoluble), finely divided silica and magnesium stearate.
  • U.S. Patent No. 5,286,754 discloses pharmaceutical formulations of ciprofloxacin that include binder based on cellulose, disintegrant based on starch, and a disintegrant based on cellulose derivatives and/or cross-linked polyvinylpyrrolidones.
  • Patent No. 6,610,327 discloses pharmaceutical preparations for oral administration that includes moxifloxacin or a salt or solvate/hydrate thereof, at least one dry binder, at least one disintegrant and at least one lubricant, characterized in that the preparation contains 2.5 % to 25% of lactose.
  • the inventors have surprisingly found that bioequivalent formulations to commercially available Avelox tablet formulations can be obtained by mtragranular and extragranular distribution of substantially water insoluble pharmaceutical excipients. Summary of the Invention In one general aspect there is provided a pharmaceutical composition that includes moxifloxacin and at least one mtragranular and extragranular substantially water insoluble excipient.
  • Embodiments of the composition may include one or more of the following features.
  • the composition may further include other pharmaceutically accepted excipients.
  • the other excipients may include one or more of binders, disintegerants, fillers, lubricants/glidants, and colorants.
  • the substantially insoluble excipients may include one or more of microcrystalline cellulose, pregelatinized starch, dicalcium phosphate dibasic, corn starch, and the like.
  • the binders may be one or more of polyvinyl pyrrolidone, hydroxypropyl cellulose and gums.
  • the fillers may be one or more of cellulose derivatives, starch derivatives, sugars, sugar alcohols, and the like.
  • the disintegrant may be one or more of pregelatinized starch, cross-linked polyvinylpyrrolidone and sodium croscarmellose sodium. In particular, the disintegrant maybe croscarmellose sodium. The disintegrant maybe from 0.5 to 10% by weight of the composition. More particularly, it may be from 2 to 5% by weight of the composition.
  • the lubricant or glidant may be one or more of fatty acids and their salts, colloidal silicon dioxide and talc. In particular, the lubricant is magnesium stearate and the glidant is colloidal silicon dioxide.
  • the lubricant may be advantageously employed in an amount of from 0.05 to 3.0% by weight of the composition. More particularly, it may be from 0.2 to 2% by weight of the composition.
  • the composition may be formulated in the form of granules filled in capsule, tablet or other suitable oral dosage form and, in particular, may be a tablet.
  • the tablet formulation may further be coated.
  • a process for preparing a pharmaceutical composition of moxifloxacin includes a) preparing an mtragranular portion by mixing moxifloxacin and at least one substantially water insoluble excipient; b) preparing an extragranular portion by mixing at least one substantially water insoluble excipient and other pharmaceutically accepted excipients; and c) compressing said mtragranular portion and extragranular portion to a tablet or filling said mtragranular portion and extragranular portion into a capsule.
  • Embodiments of the process may include one or more of the following features.
  • the mtragranular portion may further include other pharmaceutically accepted excipients.
  • the other excipients may include one or more of binders, disintegerants, fillers, lubricants/glidants, and colorants.
  • the substantially insoluble excipients may include one or more of microcrystalline cellulose, pregelatinized starch, dicalcium phosphate dibasic, corn starch, and the like.
  • the binders may be one or more of polyvinyl pyrrolidone, hydroxypropyl cellulose and gums.
  • the fillers may be one or more of cellulose derivatives, starch derivatives, sugars, sugar alcohols, and the like.
  • the disintegrant may be one or more of pregelatinized starch, cross-linked polyvinylpyrrolidone and sodium croscarmellose sodium. In particular, the disintegrant maybe croscarmellose sodium. The disintegrant maybe from 0.5 to 10% by weight of the composition. More particularly, it may be from 2 to 5% by weight of the composition.
  • the lubricant or glidant may be one or more of fatty acids and their salts, colloidal silicon dioxide and talc. In particular, the lubricant is magnesium stearate and the glidant is colloidal silicon dioxide.
  • the lubricant may be advantageously employed in an amount of from 0.05 to 3.0% by weight of the composition. More particularly, it may be from 0.2 to 2% by weight of the composition.
  • Avelox tablet formulations can be obtained by mtragranular and extragranular distribution of substantially water insoluble pharmaceutical excipients, with or without the inclusion of lactose.
  • the formulation maybe in the form of granules filled in capsule, tablet or other suitable oral dosage form.
  • moxifloxacin refers its free base, salts, solvates, enantiomers or mixtures thereof.
  • the salts of moxifloxacin include, for example, acid addition salts, such as salts of hydrochloric acid, sulphuric acid, acetic acid, lactic acid, etc., and also salts with bases, such as sodium hydroxide, potassium hydroxide, etc. hi particular, the acid addition salt may be moxifloxacin hydrochloride monohydrate.
  • acid addition salt may be moxifloxacin hydrochloride monohydrate.
  • substantially insoluble refers to the solubility less than that of lactose.
  • substantially insoluble excipients include microcrystalline cellulose, pregelatinized starch, dicalcium phosphate dibasic, corn starch, and the like.
  • the mtragranular and extragranular portions may also contain other pharmaceutically acceptable excipients such as binders, disintegerants, fillers, lubricants/glidants, colorants, and the like.
  • Suitable binders may include one or more of polyvinyl pyrrolidone, hydroxypropyl cellulose, gums and the like.
  • Suitable fillers may include one or more of cellulose derivatives, starch derivatives, sugars, sugar alcohols and the like.
  • Suitable disintegrants include one or more of pregelatinized starch, cross-linked polyvinylpyrrolidone, sodium croscarmellose sodium and the like. In particular, the disintegrant may be croscarmellose sodium.
  • the pharmaceutical composition may contain from 0.5 to 10%, preferably from 2 to 5%, of the disintegrant.
  • Suitable lubricants and glidants may include one or more of fatty acids and their salts, colloidal silicon dioxide, talc and the like.
  • the lubricant is a salt of a fatty acid, for example, magnesium stearate.
  • the glidant is colloidal silicon dioxide.
  • the lubricant is advantageously employed in an amount of from 0.05 to 3.0%, for example, 0.2 to 2%.
  • the colors maybe selected from any FDA approved colors for internal use.
  • the formulation may optionally be coated.
  • the dosage form may be in tablet or capsule form, however, the tablet form is particularly suitable.
  • the tablet may further be coated.
  • any formulation which is customary in pharmaceutical technology, such as, for example, those based on hydroxypropyl methyl cellulose (HPMC) and/or polyethylene glycol of various molecular weights may be used.
  • HPMC hydroxypropyl methyl cellulose
  • polyethylene glycol of various molecular weights
  • the formulations prepared according to the present invention were found to be bioeqivalent to the Avelox tablet dosage form available in the US market by Bayer.
  • the following data shows the phannacokinetic data of tablet formulation of present invention and Avelox tablet available in US market carried out in 12 healthy human volunteers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à des compositions pharmaceutiques à base de moxifloxacine, ainsi qu'à des procédés de préparation de ces compositions.
PCT/IB2004/002875 2003-09-03 2004-09-03 Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation WO2005020998A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04769278A EP1663226A1 (fr) 2003-09-03 2004-09-03 Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1099DE2003 2003-09-03
IN1099/DEL/2003 2003-09-03

Publications (1)

Publication Number Publication Date
WO2005020998A1 true WO2005020998A1 (fr) 2005-03-10

Family

ID=34259939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002875 WO2005020998A1 (fr) 2003-09-03 2004-09-03 Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation

Country Status (3)

Country Link
EP (1) EP1663226A1 (fr)
WO (1) WO2005020998A1 (fr)
ZA (1) ZA200602497B (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2010066385A1 (fr) 2008-12-08 2010-06-17 Ratiopharm Gmbh Moxifloxacine compactée
WO2009135646A3 (fr) * 2008-05-05 2011-03-17 Farmaprojects, Sa Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
WO2013097003A1 (fr) 2011-12-26 2013-07-04 Ems S/A. Composition pharmaceutique solide comprenant un antibiotique de la famille des quinolones et son procédé d'obtention
WO2014146775A1 (fr) * 2013-03-19 2014-09-25 Pharmathen S.A. Composition pharmaceutique comprenant un agent antibactérien de fluoroquinolone et son procédé de préparation
CN104622821A (zh) * 2013-11-13 2015-05-20 武汉先路医药科技有限公司 解决溶出行为受制粒时间影响问题的莫西沙星片剂配方
CN106074413A (zh) * 2016-07-20 2016-11-09 南通雅本化学有限公司 一种含有莫西沙星的药物组合物
CN109045034A (zh) * 2018-09-29 2018-12-21 哈尔滨珍宝制药有限公司 一种盐酸莫西沙星药物组合物及其制备方法和应用
WO2021257461A1 (fr) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990517A (en) * 1988-07-15 1991-02-05 Bayer Aktiengesellschaft 7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives
US6610327B1 (en) * 1998-11-10 2003-08-26 Bayer Aktiengesellschaft Pharmaceutical moxifloxacin preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990517A (en) * 1988-07-15 1991-02-05 Bayer Aktiengesellschaft 7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives
US6610327B1 (en) * 1998-11-10 2003-08-26 Bayer Aktiengesellschaft Pharmaceutical moxifloxacin preparation

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2009135646A3 (fr) * 2008-05-05 2011-03-17 Farmaprojects, Sa Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
EP2837376A3 (fr) * 2008-12-08 2015-03-25 ratiopharm GmbH Moxifloxacine compactée
EP2364141A1 (fr) 2008-12-08 2011-09-14 Ratiopharm GmbH Moxifloxacine compactée
EP2735307A1 (fr) 2008-12-08 2014-05-28 Ratiopharm GmbH Moxifloxacine Compactée
EP2837376A2 (fr) 2008-12-08 2015-02-18 ratiopharm GmbH Moxifloxacine compactée
WO2010066385A1 (fr) 2008-12-08 2010-06-17 Ratiopharm Gmbh Moxifloxacine compactée
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
WO2013097003A1 (fr) 2011-12-26 2013-07-04 Ems S/A. Composition pharmaceutique solide comprenant un antibiotique de la famille des quinolones et son procédé d'obtention
WO2014146775A1 (fr) * 2013-03-19 2014-09-25 Pharmathen S.A. Composition pharmaceutique comprenant un agent antibactérien de fluoroquinolone et son procédé de préparation
CN104622821A (zh) * 2013-11-13 2015-05-20 武汉先路医药科技有限公司 解决溶出行为受制粒时间影响问题的莫西沙星片剂配方
CN106074413A (zh) * 2016-07-20 2016-11-09 南通雅本化学有限公司 一种含有莫西沙星的药物组合物
CN109045034A (zh) * 2018-09-29 2018-12-21 哈尔滨珍宝制药有限公司 一种盐酸莫西沙星药物组合物及其制备方法和应用
CN109045034B (zh) * 2018-09-29 2021-04-13 哈尔滨珍宝制药有限公司 一种盐酸莫西沙星药物组合物及其制备方法和应用
WO2021257461A1 (fr) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne

Also Published As

Publication number Publication date
EP1663226A1 (fr) 2006-06-07
ZA200602497B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
ZA200602497B (en) Pharmaceutical compositions of moxifloxacin and processes for their preparation
JP4463875B2 (ja) 医薬組成物
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
EP3409272B1 (fr) Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
WO2018197088A1 (fr) Composition pharmaceutique de comprimés comprenant de l'eltrombopag olamine
GB2414668A (en) Sustained release delivery system for tetracycline compounds
CZ291999B6 (cs) Tableta pro léčbu migrény a způsob její přípravy
EP1165065B1 (fr) Comprimes a avaler a teneur elevee en n-acetylcysteine
WO2005060941A1 (fr) Composition antibiotique a liberation prolongee
CZ124497A3 (en) Oral preparations with prolonged release of cisaprid
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
AU2005235237A1 (en) Clarithromycin extended release formulation
US20110223245A1 (en) Controlled-release formulations of pramipexole
US20110262540A1 (en) Solid Pharmaceutical Composition Comprising Exemestane
US20080260785A1 (en) Paroxetine compositions
US20060030581A1 (en) Mannitol formulation for integrin receptor antagonist
JP6123795B2 (ja) 放出制御医薬組成物
WO2011086577A2 (fr) Composition pharmaceutique de moxifloxacine et ses sels pharmaceutiquement acceptables
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
JPH092953A (ja) バルフロキサシン製剤
EP2233131A1 (fr) Composition pharmaceutique contenant de la lévodopa, un inhibiteur de la catéchol-O-méthyl-transférase et de la carbidopa
WO2023232215A1 (fr) Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation
WO2017114597A1 (fr) Formes pharmaceutiques comprenant du ((cis)-n-(4-(diméthylamino) -1,4-diphénylcyclohexyl)-n-méthylcinnamamide
WO2009076983A2 (fr) Composition pharmaceutique améliorée contenant un agoniste dopaminergique non ergoté et procédé de préparation de celle-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1422/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/02497

Country of ref document: ZA

Ref document number: 200602497

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004769278

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004769278

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004769278

Country of ref document: EP